

# MARCH 21 & 22 2024

COPENHAGEN/MALMÖ SCANDIC TRIANGELN, MALMÖ

# Low profile devices make it all much easier but are they durable?

### Mauro Gargiulo



Vascular Surgery University of Bologna - DIMEC IRCCS – University Hospital S. Orsola Bologna, Italy mauro.gargiulo2@unibo.it



# Low profile devices make it all much easier but are they durable?

Speaker Name: Prof Mauro Gargiulo

I have the following potential conflicts of interest to report:

X Consulting : Cook Medical, WL Gore & Associates, Medtronic

Employment in industry

Stockholder of a healthcare company

Owner of a healthcare company

X Principal Invesigator Expand Registry VBX 17-04





How many patients with infrarenal aneurysms are candidates for endovascular repair? *The Northern California Experience Arko FR et al. J Endovasc Ther 2004; 11: 33-40* 

### 98 / 220 pts (45%) anatomically unsuitable candidates for EVAR

Primary reason for endovascular repair ineligibility by gender

	Men (n=68)	Women (n=30)	Totals (n=98)
Neck characteristics	49	24	73 (74%)
Proximal neck length <15 mm	25	16	43 (44%)
Proximal neck diameter >26 mm	18	7	25 (25%)
Tortuous/calcified neck	6	1	7 (7%)
Iliac artery characteristics	12	4	16 (16%)
Stenosis/occlusion/tortuosity	4	2	6 (6%)
Aneurysms	8	2	10 (10%)
Other anatomical characteristics	4	1	5 (5%)
Accessory renal arteries	1	0	1 (1%)
One kidney and accessory renal artery	1	0	1 (1%)
Small diameter of aortic bifurcation	2	1	3 (3%)
Poor quality CT scan	3	1	4 (4%)

CT: computed tomography.


# Identifying and grading factors that modify the outcome of endovascular aortic aneurysm repair

Elliot L. Chaikof, MD, PhD, Mark F. Fillinger, MD, Jon S. Matsumura, MD, Robert B. Rutherford, MD, Geoffrey H. White, MD, Jan D. Blankensteijn, MD, Victor M. Bernhard, MD, Peter L. Harris, MD, K. Craig Kent, MD, James May, MD, Frank J. Veith, MD, and Christopher K. Zarins, MD

J Vasc Surg 2002;35:1061

Hostile Iliac Arteries

	Absent = 0	$\mathbf{Mild} = 1$	Moderate = 2	Severe = 3
CALCIFICATION	none	< 25% vessel length	25-50% vessel length	> 50% vessel length
DIAMETER	>10 mm	8-10 mm	7-8 mm	< 7 mm
Occlusive disease	no	Stenosis > 7 mm or > 3 cm long	Focal stenosis < 7 mm and < 3 mm length	Stenosis < 7 mm and > 3 mm length
ANGULATION AND TORTUOSITY				
Iliac Tortuosity Index Iliac Angle	$\tau < 1.25$ 160-180°	τ 1.25-1.5 121-159°	τ 1.5 – 1.6 90-120°	τ > 1.6 < 90°
ILIAC ARTERY SEALING ZONE				
Length Diameter	> 30 mm < 12.5 mm	20-30 mm 12.5-14.5 mm	10-20 mm 14.5-17 mm	< 10 mm > 17 mm



# Identifying and grading factors that modify the outcome of endovascular aortic aneurysm repair

Elliot L. Chaikof, MD, PhD, Mark F. Fillinger, MD, Jon S. Matsumura, MD, Robert B. Rutherford, MD, Geoffrey H. White, MD, Jan D. Blankensteijn, MD, Victor M. Bernhard, MD, Peter L. Harris, MD, K. Craig Kent, MD, James May, MD, Frank J. Veith, MD, and Christopher K. Zarins, MD J Vasc Surg 2002;35:1061


Hostile Iliac Arteries

	Al	osent = 0	$\mathbf{Mild} = 1$	Moderate = 2	Severe = 3
•	The key role in the exist the continuous evolution and especially of stem EVAR.	lution of	f endovasc	ular technique	s, materials

• Manufacturers have developed new stent grafts with the enhanced sealing capability and delivery systems with lower profiles to allow an endovascular approach even in patients with complex and small access vessels

# AAA – Bifurcated Endograft for EVAR

- Stent graft
- Low-profile stent graft (main body 16 20 F OD)
- Ultra-low profie stent-graft (main body  $\leq 16$  F OD)





<b>Company Name</b>	Product Name	Main Body Delivery System Profile: Device OD (F)
Artivion, Inc.	E-tegra Stent Graft System	18 (<32 mm), 20 (≥32 mm)
Cook Medical	Zenith Alpha Abdominal	18 (22–32 mm grafts), 20 (36 mm)
Cook Medical	Zenith Flex with Z-Trak	21, 23, 26
Cordis	Incraft AAA Stent Graft System	14 (≤ 30 mm), 16 (34 mm)
Lombard – Medical	Aorfix	18
Lombard – Medical	Altura	14
Lombard - Medical	Minos	14 F (22-28 mm) ; 16 F (30-34 mm)
Endologix	Ovation	14 (≤ 29 mm),15 (34 mm)
Gore & Associates	Gore Excluder C3	16 (< 28.5 mm),18 (≥ 28.5 mm)
Gore & Associates	Gore Excluder Conformable	16 (≤28.5 mm),18 (>28.5 mm)
Medtronic	Endurant II AAA Stent Graft System	18 (≤ 28 mm), 20 (>28 mm)
Medtronic	Endurant II AUI Stent Graft System	18 (≤ 28 mm), 20 (>28 mm)
Medtronic	Endurant IIs AAA Stent Graft System	18 (≤ 28 mm), 20 (>28 mm)
Terumo Aortic	Anaconda	20 (≤ 30.5-mm); 22 (≥ 32 mm)
Terumo Aortic	Treo	18, 19 (≥ 30 main )



Vascular Surgery – University of Bologna DIMEC, IRCCS University Hospital S. Orsola, Bologna, Italy

#### • Low-profile stent graft (main body 16 - 20 F OD)

<b>Company Name</b>	Product Name	Main Body Delivery System Profile: Device OD (F)
Artivion, Inc.	E-tegra Stent Graft System	18 (<32 mm), 20 (≥32 mm)
<b>Cook Medical</b>	Zenith Alpha Abdominal	18 (22–32 mm grafts), 20 (36 mm)
Cook Medical	Zenith Flex with Z-Trak	21, 23, 26
Cordis	Incraft AAA Stent Graft System	14 (≤ 30 mm), 16 (34 mm)
Lombard – Medical	Aorfix	18
Lombard – Medical	Altura	14
Lombard - Medical	Minos	14 F (22-28 mm) ; 16 F (30-34 mm)
Endologix	Ovation	14 (≤ 29 mm),15 (34 mm)
Gore & Associates	Gore Excluder C3	16 (< 28.5 mm),18 (≥ 28.5 mm)
Gore & Associates	Gore Excluder Conformable	16 (≤ 28.5 mm),18 (> 28.5 mm)
Medtronic	Endurant II AAA Stent Graft System	18 (≤ 28 mm), 20 (>28 mm)
Medtronic	Endurant II AUI Stent Graft System	18 (≤ 28 mm), 20 (>28 mm)
Medtronic	Endurant IIs AAA Stent Graft System	18 (≤ 28 mm), 20 (>28 mm)
Terumo Aortic	Anaconda	$20 (\leq 30.5\text{-mm}); 22 (\geq 32 \text{ mm})$
Terumo Aortic	Treo	18, 19 (≥ 30 main )



Vascular Surgery – University of Bologna DIMEC, IRCCS University Hospital S. Orsola, Bologna, Italy

#### • Ultra-low profie stent-graft (main body $\leq 16$ F OD)

Company Name	Product Name	Main Body Delivery System Profile Device OD (F)
Artivion, Inc.	E-tegra Stent Graft System	18 (<32 mm), 20 (≥32 mm)
Cook Medical	Zenith Alpha Abdominal	18 (22–32 mm grafts), 20 (36 mm)
Cook Medical	Zenith Flex with Z-Trak	21, 23, 26
Cordis	Incraft AAA Stent Graft System	14 (≤ 30 mm), 16 (34 mm)
Lombard – Medical	Aorfix	18
Lombard – Medical	Altura	14
Lombard - Medical	Minos	14 F (22-28 mm) ; 16 F (30-34 mm)
Endologix	Ovation	14 (≤ 29 mm),15 (34 mm)
Gore & Associates	Gore Excluder C3	16 (< 28.5 mm),18 (≥ 28.5 mm)
Gore & Associates	Gore Excluder Conformable	16 (≤ 28.5 mm),18 (> 28.5 mm)
Medtronic	Endurant II AAA Stent Graft System	18 (≤ 28 mm), 20 (>28 mm)
Medtronic	Endurant II AUI Stent Graft System	18 (≤ 28 mm), 20 (>28 mm)
Medtronic	Endurant IIs AAA Stent Graft System	18 (≤ 28 mm), 20 (>28 mm)
Terumo Aortic	Anaconda	20 (≤ 30.5-mm); 22 (≥ 32 mm)
Terumo Aortic	Treo	18, 19 (for 30, 33, 36 main bodies)



# Low profile devices make it all much easier but are they durable?

#### • Ultra-low profie stent-graft (main body $\leq 16$ F OD)

Company Name	Product Name	Main Body Delivery System Profile Device OD (F)
Artivion, Inc.	E-tegra Stent Graft System	18 (<32 mm), 20 (≥32 mm)
Cook Medical	Zenith Alpha Abdominal	18 (22–32 mm grafts), 20 (36 mm)
Cook Medical	Zenith Flex with Z-Trak	21, 23, 26
Cordis	Incraft AAA Stent Graft System	14 (≤ 30 mm), 16 (34 mm)
Lombard – Medical	Aorfix	18
Lombard – Medical	Altura	14
Lombard - Medical	Minos	14 F (22-28 mm) ; 16 F (30-34 mm)
Endologix	Ovation	14 (≤ 29 mm),15 (34 mm)
Gore & Associates	Gore Excluder C3	16 (< 28.5 mm),18 (≥ 28.5 mm)
Gore & Associates	Gore Excluder Conformable	16 (≤ 28.5 mm),18 (> 28.5 mm)
Medtronic	Endurant II AAA Stent Graft System	18 (≤ 28 mm), 20 (>28 mm)
Medtronic	Endurant II AUI Stent Graft System	18 (≤ 28 mm), 20 (>28 mm)
Medtronic	Endurant IIs AAA Stent Graft System	18 (≤ 28 mm), 20 (>28 mm)
Terumo Aortic	Anaconda	20 (≤ 30.5-mm); 22 (≥ 32 mm)
Terumo Aortic	Treo	18, 19 (for 30, 33, 36 main bodies)



Gianmarco de Donato, MD, PhD,<sup>a</sup> Edoardo Pasqui, MD,<sup>a</sup> Giovanni Nano, MD, PhD,<sup>b</sup> Massimo Lenti, MD, PhD,<sup>c</sup> Nicola Mangialardi, MD, PhD,<sup>d</sup> Francesco Speziale, MD, PhD,<sup>e</sup> Mauro Ferrari, MD, PhD,<sup>f</sup> Stefano Michelagnoli, MD, PhD,<sup>9</sup> Matteo Tozzi, MD, PhD,<sup>h</sup> and Giancarlo Palasciano, MD, PhD,<sup>a</sup> on behalf of the LoLopro Registry Collaborators,<sup>\*</sup> Siena, Milan, Perugia, Rome, Pisa, Florence, Insubria, Italy

(J Vasc Surg 2022;75:1242-52.)

- This study aims to report long-term outcomes (beyond 5 years) from a multicenter registry, including a daily practice cohort of patients electively treated for AAA with low-profile stent grafts.
- A multivariate analysis was carried out to evaluate the influence of anatomical factors and device materials on primary clinical success and reintervention rates.

**Table I.** Baseline demographics and aortic anatomical features of the total study population (n = 619) and endograft subgroup comparison (Ovation, n = 373; Incraft, n = 111; Zenith LP, n = 135)

	All patients (n = 619)	Ovation (n = 373)	Incraft (n = 111)	Zenith LP (n = 135)	P-value
Clinical variables					
Age, years	75.3 ± 7.9	74.9 ± 8.1	75.3 ± 7.7	76.6 ± 7.7	.085
Male	549 (88.7)	329 (88.2)	95 (85.6)	125 (92.6)	.2
Hypertension	437 (70.6)	276 (74)	85 (76.6)	76 (56.2)	.0002
DM	76 (12.3)	42 (11.3)	15 (13.5)	19 (14.1)	.6
Dyslipidemia	141 (22.8)	83 (22.3)	27 (24.3)	31 (23)	.9
Smoking	109 (17.6)	72 (19.3)	17 (15.3)	20 (14.8)	.4
COPD	71 (11.5)	39 (10.4)	14 (12.6)	18 (13.3)	.6
CAD	159 (25.7)	86 (23.1)	32 (28.8)	41 (30.3)	.17
AF	49 (7.9)	21 (5.6)	13 (11.7)	15 (11.1)	.03
Chronic renal disease	70 (11.3)	37 (9.9)	15 (13.5)	18 (13.3)	.4
Smoking	181 (29.2)	109 (29.2)	29 (26.1)	43 (31.8)	.6
Congestive heart failure	93 (15)	57 (15.2)	15 (13.5)	21 (15.5)	.8
Cerebrovascular disease	66 (10.6)	34 (9.1)	15 (13.5)	17 (12.5)	.3
History of cancer	65 (10.5)	39 (10.4)	10 (9)	16 (11.8)	.7
ASA classification					
141	266 (42.9)	171 (45.8)	43 (38.7)	52 (38.5)	.2
III-IV	353 (57.1)	202 (54.2)	68 (61.2)	83 (61.4)	.2
Anatomical features					
AAA diameter, mm	56.9 ± 7.9	55.2 ± 8.2	57.5 ± 9.5	58.5 ± 9.2	.0003
Aortic neck angle >60°	120 (19.4)	78 (20.9)	26 (23.4)	16 (11.9)	.007
Short aortic neck (<10 mm)	117 (18.9)	103 (27.6)	7 (6.3)	7 (5.2)	<.0001
Neck calcification >50%	81 (13.1)	42 (11.3)	21 (18.9)	18 (13.3)	.1
Neck thrombus > 50%	76 (12 2)	77 (0.0)	16 (14 4)	27 (17)	07
lliac calcifications	230 (37.2)	149 (39.9)	4O (36)	41 (30.4)	.13
lliac tortuosity index >1.5	201 (32.5)	126 (33.8)	36 (32.4)	39 (28.9)	.5
Small iliac access <6 mm	161 (26)	99 (26.5)	39 (35.1)	2317	.005

AAA, Abdominal aortic aneurysm; AF, atrial fibrillation; ASA, American Society of Anesthesiologists; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus.

Data are presented as number (%) or mean ± standard deviation.

Boldface P values indicate statistical significance.

Gianmarco de Donato, MD, PhD,<sup>a</sup> Edoardo Pasqui, MD,<sup>a</sup> Giovanni Nano, MD, PhD,<sup>b</sup> Massimo Lenti, MD, PhD,<sup>c</sup> Nicola Mangialardi, MD, PhD,<sup>d</sup> Francesco Speziale, MD, PhD,<sup>e</sup> Mauro Ferrari, MD, PhD,<sup>f</sup> Stefano Michelagnoli, MD, PhD,<sup>g</sup> Matteo Tozzi, MD, PhD,<sup>h</sup> and Giancarlo Palasciano, MD, PhD,<sup>a</sup> on behalf of the LoLopro Registry Collaborators,<sup>\*</sup> Siena, Milan, Perugia, Rome, Pisa, Florence, Insubria, Italy

(J Vasc Surg 2022;75:1242-52.)

- Primary Technical Success 98.1%
- Assisted Primary Technical Success 99.4%
- 30 days Mortality rate 0.5%

**Technical success** relates to periprocedural events that occur from the initiation of the procedure and extend through the first 24-hour postoperative period.


**Primary technical success** is defined on an intent-to-treat basis. It requires the successful introduction and deployment of the device in the absence of surgical conversion or mortality, type I or III endoleaks, or graft limb obstruction

Gianmarco de Donato, MD, PhD,<sup>a</sup> Edoardo Pasqui, MD,<sup>a</sup> Giovanni Nano, MD, PhD,<sup>b</sup> Massimo Lenti, MD, PhD,<sup>c</sup> Nicola Mangialardi, MD, PhD,<sup>d</sup> Francesco Speziale, MD, PhD,<sup>e</sup> Mauro Ferrari, MD, PhD,<sup>f</sup> Stefano Michelagnoli, MD, PhD,<sup>g</sup> Matteo Tozzi, MD, PhD,<sup>h</sup> and Giancarlo Palasciano, MD, PhD,<sup>a</sup> on behalf of the LoLopro Registry Collaborators,<sup>\*</sup> Siena, Milan, Perugia, Rome, Pisa, Florence, Insubria, Italy

(J Vasc Surg 2022;75:1242-52.)

#### Mean follow up : $56.8 \pm 2.8$ months

Primary Clinical Success в Primary Clinical Success Comparison Α - Study Population Ovation 100 100 Incraft \* 72.1% Zenith LP itage age 88.3% 50 50 Ovation vs. Incraft: p=0.32 Ovation vs. Zenith LP: p<0.0001 Zenith LP vs incraft: p=0.28 12 24 36 48 60 72 84 12 24 36 48 60 72 Months Month



**Clinical success** is defined as successful deployment of the endovascular device at the intended location without death as a result of aneurysm-related treatment, type I or III endoleak, graft infection or thrombosis, aneurysm expansion (diameter >5 mm, or volume >5%), aneurysm rupture, or conversion to open repair.

**Fig 1.** Kaplan-Meier (KM) curve analyses. In the left column, KM graphs of the entire study population (N = 619) for primary clinical success (**A**), freedom from reintervention (**C**), and freedom from type I/III endoleak (**E**). In the right column, KM graphs comparing the three investigative devices (Ovation, n = 373; Incraft, n = 111; Zenith LP, n = 135) for primary clinical success (**B**), freedom from reintervention (**D**), and freedom from type I/III endoleak (**F**).

Cianmarco de Donato, MD, PhD,<sup>a</sup> Edoardo Pasqui, MD,<sup>a</sup> Giovanni Nano, MD, PhD,<sup>b</sup> Massimo Lenti, MD, PhD,<sup>c</sup> Nicola Mangialardi, MD, PhD,<sup>d</sup> Francesco Speziale, MD, PhD,<sup>e</sup> Mauro Ferrari, MD, PhD,<sup>f</sup> Stefano Michelagnoli, MD, PhD,<sup>9</sup> Matteo Tozzi, MD, PhD,<sup>h</sup> and Ciancarlo Palasciano, MD, PhD,<sup>a</sup> on behalf of the LoLopro Registry Collaborators,<sup>\*</sup> Siena, Milan, Perugia, Rome, Pisa, Florence, Insubria, Italy


(J Vasc Surg 2022;75:1242-52.)


#### Mean follow up : $56.8 \pm 2.8$ months

### Multivariable analysis

- Iliac tortuosity (hazard ratio [HR], 2.053; 95% confidence interval [CI], 1.197-3.512; P <sup>1</sup>/<sub>4</sub> .008) and endograft Zenith LP (HR, 3.818; 95% CI, 2.128-6.9; P < .0001) were found as significant independent predictors of clinical failure.

- Iliac tortuosity (HR, 1.761; 95% CI, 1.028-2.992; P <sup>1</sup>/<sub>4</sub> .003) and endograft Zenith LP (HR, 2.418; 95% CI, 1.332-4.362; P <sup>1</sup>/<sub>4</sub> .003) were found to be also independent predictors of reinterventions.






**Fig 1.** Kaplan-Meier (KM) curve analyses. In the left column, KM graphs of the entire study population (N = 619) for primary clinical success (A), freedom from reintervention (C), and freedom from type I/III endoleak (E). In the right column, KM graphs comparing the three investigative devices (Ovation, n = 373; Incraft, n = 111; Zenith LP, n = 135) for primary clinical success (B), freedom from reintervention (D), and freedom from type I/III endoleak (F).

Gianmarco de Donato, MD, PhD,<sup>a</sup> Edoardo Pasqui, MD,<sup>a</sup> Giovanni Nano, MD, PhD,<sup>b</sup> Massimo Lenti, MD, PhD,<sup>c</sup> Nicola Mangialardi, MD, PhD,<sup>d</sup> Francesco Speziale, MD, PhD,<sup>e</sup> Mauro Ferrari, MD, PhD,<sup>f</sup> Stefano Michelagnoli, MD, PhD,<sup>9</sup> Matteo Tozzi, MD, PhD,<sup>h</sup> and Giancarlo Palasciano, MD, PhD,<sup>a</sup> on behalf of the LoLopro Registry Collaborators,<sup>\*</sup> Siena, Milan, Perugia, Rome, Pisa, Florence, Insubria, Italy


(J Vasc Surg 2022;75:1242-52.)



**Fig 2.** Kaplan-Meier (KM) curve analyses. In the left column, KM graphs of the entire study population (n = 619) for limb patency (**A**), overall survival (**C**), and freedom from abdominal aortic aneurysm (AAA)-related deaths (**E**). In the right column, KM graphs comparing the three investigative devices (Ovation, n = 373; Incraft, n = 111; Zenith LP, n = 135) for limb patency (**B**), overall survival (**D**), and freedom from AAA-related deaths (**F**).


Gianmarco de Donato, MD, PhD,<sup>a</sup> Edoardo Pasqui, MD,<sup>a</sup> Giovanni Nano, MD, PhD,<sup>b</sup> Massimo Lenti, MD, PhD,<sup>c</sup> Nicola Mangialardi, MD, PhD,<sup>d</sup> Francesco Speziale, MD, PhD,<sup>e</sup> Mauro Ferrari, MD, PhD,<sup>f</sup> Stefano Michelagnoli, MD, PhD,<sup>9</sup> Matteo Tozzi, MD, PhD,<sup>h</sup> and Giancarlo Palasciano, MD, PhD,<sup>a</sup> on behalf of the LoLopro Registry Collaborators,<sup>\*</sup> Siena, Milan, Perugia, Rome, Pisa, Florence, Insubria, Italy

(J Vasc Surg 2022;75:1242-52.)



### CONCLUSIONS

This retrospective study shows that patients treated with low-profile stent grafts have acceptable long-term outcomes. Overall survival and AAA-related deaths were in line with those reported for traditional devices. Long-term surveillance and reintervention, when necessary, remain crucial to guarantee durability. The design evolution toward low-profile platforms seems not to affect the type of complication during the follow-up.



ion vs. Incraft: p=0.72 vs. Zenith LP: p=0.17 h LP vs Incraft: p=0.25 1 1 1 0 72 84

Months

#### Months

**Fig 2.** Kaplan-Meier (KM) curve analyses. In the left column, KM graphs of the entire study population (n = 619) for limb patency (**A**), overall survival (**C**), and freedom from abdominal aortic aneurysm (AAA)-related deaths (**E**). In the right column, KM graphs comparing the three investigative devices (Ovation, n = 373; Incraft, n = 111; Zenith LP, n = 135) for limb patency (**B**), overall survival (**D**), and freedom from AAA-related deaths (**F**).

Ten-year single-center outcomes following endovascular repair for abdominal aortic aneurysm using the INCRAFT device

Hirotsugu Ozawa, MD, PhD, Takao Ohki, MD, PhD, Kota Shukuzawa, MD, PhD, Kentaro Kasa, MD, Yuta Yamada, MD, Hikaru Nakagawa, MD, Miyo Shirouzu, MD, Makiko Omori, MD, Soichiro Fukushima, MD, Hiromasa Tachihara, MD, PhD



- 2012-2013
- Single center, retrospective study
- 30 pts with AAA
- INCRAFT device
- Median Follow up:
  - ·p·
- Follow up rate:



10 years 96.7%

100%

5 years

# Clinical Success100%MAE0%Periop. procedure-related complications0%

Ten-year single-center outcomes following endovascular repair for abdominal aortic aneurysm using the INCRAFT device

Hirotsugu Ozawa, MD, PhD, Takao Ohki, MD, PhD, Kota Shukuzawa, MD, PhD, Kentaro Kasa, MD, Yuta Yamada, MD, Hikaru Nakagawa, MD, Miyo Shirouzu, MD, Makiko Omori, MD, Soichiro Fukushima, MD, Hiromasa Tachihara, MD, PhD

# **10-years Results**


#### Table III. Follow-up outcomes

Variables	Value
Total follow-up duration, months	125 (98-131)
Clinical follow-up duration, months	119 (61-130)
Aneurysm sac status	
Shrinkage	11 (36.7)
Stable	8 (26.7)
Growth	11 (36.7)
Reintervention	
Individual number of cases	10 (33.3)
Cumulative number of cases	15
Reasons for reintervention (cumulative number)	
Type Ia endoleak	5
Type Ib endoleak	1
Type II endoleak	7
Type IIIb endoleak	1
Endotention	2
Late open conversion	6 (20.0)
Open aneurysmorrhaphy with stent graft preservation	5 (16.7)
Open surgical repair with stent graft explantation	1 (3.3)
Limb occlusion	0
Significant proximal neck dilatation	12 (40.0)
Aneurysm-related death	0 (0.0)
All-cause death	9 (30.0)

Ten-year single-center outcomes following endovascular repair for abdominal aortic aneurysm using the INCRAFT device

Hirotsugu Ozawa, MD, PhD, Takao Ohki, MD, PhD, Kota Shukuzawa, MD, PhD, Kentaro Kasa, MD, Yuta Yamada, MD, Hikaru Nakagawa, MD, Miyo Shirouzu, MD, Makiko Omori, MD, Soichiro Fukushima, MD, Hiromasa Tachihara, MD, PhD

# **10-years Results**



SVS | tttt.

JVS Vascular Surgery

Ten-year single-center outcomes following endovascular repair for abdominal aortic aneurysm using the INCRAFT device

Hirotsugu Ozawa, MD, PhD, Takao Ohki, MD, PhD, Kota Shukuzawa, MD, PhD, Kentaro Kasa, MD, Yuta Yamada, MD, Hikaru Nakagawa, MD, Miyo Shirouzu, MD, Makiko Omori, MD, Soichiro Fukushima, MD, Hiromasa Tachihara, MD, PhD

Figure I.	Journal Pro-proof	
(A) Freedom from aneurysm-related mortality	(B) Freedom from all-cause mortality	(C) Freedom from reintervention

SVS | http://

JVS Vascular Surgery

• Long-term outcomes beyond 10 years of EVAR with the INCRAFT stent graft showed no aneurysm-related mortality.

**10-years Results** 

• Sac growth occurred persistently throughout the follow-up period, resulting in a number of reinterventions especially after the seventh year following EVAR, which highlights that careful postoperative surveillance and appropriate reintervention, if indicated, are essential to achieve favorable long-term outcomes of the INCRAFT device as well as any endografts.

y.	8												8.													10											
é	1	Numbe	r at ri	sk									9	Num	ber at	risk										6	Numbe	r at ris	sk								
8	a.	30	28	27	24	22	21	20	17	17	14	5	8.	3	03	0	29	28	23	22	21	17	15	14	4	8	29	23	22	20	16	14	13	11	11	6	1
e	0	12	24	36	48	- 60	72	84	96	108	120	132	0	0 1	2 2	4	35	48	60	72	84	98	108	120	132		0 12	24	36	48	60	72	84	96	108	120	132
					Mo	nths foi	iowing	EVAR										Mont	hs folk	owing	EVAR									Mont	ths follo	wing E	EVAR				

#### Early Results of Elective Endovascular Repair of Infrarenal Abdominal Aortic Aneurysms With the Minos<sup>™</sup> Stent-Graft System




Journal of Endovascular Therapy 1-8 © The Author(s) 2023 CODE Article reuse guidelines: sagepub.com/Journals-permissions DOI: 10.1177/15266028231172379 www.jevt.org Sage

Georgios A. Pitoulias, MD, PhD<sup>1,\*</sup>, Apostolos G. Pitoulias, MD, MSc<sup>1,\*</sup>, Dimitrios A. Chatzelas, MD, MSc<sup>1</sup>, Theodosia Zampaka, MD, MSc<sup>1</sup>, Charalampos Loutradis, MD, MSc<sup>1</sup>, Anastasios Potouridis, MD, MSc<sup>1</sup>, and Maria D. Tachtsi, MD, PhD<sup>1</sup>

- Endograft first introduced in China in 2019
- Conformite Europeenne (CE) mark in September 2019

#### • Stent Graft System

- PN length no less than 15 mm.
- hydrophilic delivery system with ultra-low
- (14F–16F) outer sheath profile,
- three-piece design
- suprarenal fixation with 8 laser-cut M-bare stents and integrated barbs
- 41 pts
- Hostile iliac arteries 26.8%
- Median clinical follow up 12.4 months




**Clinical Investigation** 

#### Early Results of Elective Endovascular Repair of Infrarenal Abdominal Aortic Aneurysms With the Minos<sup>TM</sup> Stent-Graft System



Journal of Endovascular Therapy I-8 © The Author(s) 2023 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/15266028231172379 ww.jevt.org Sage

Georgios A. Pitoulias, MD, PhD<sup>1,\*</sup>, Apostolos G. Pitoulias, MD, MSc<sup>1,\*</sup>, Dimitrios A. Chatzelas, MD, MSc<sup>1</sup>, Theodosia Zampaka, MD, MSc<sup>1</sup>, Charalampos Loutradis, MD, MSc<sup>1</sup>, Anastasios Potouridis, MD, MSc<sup>1</sup>, and Maria D. Tachtsi, MD, PhD<sup>1</sup>



#### Table 2. Outcomes.

Mean±SD or
Median—IQR (range)
or N—%

#### Follow-up

Clinical, months	12.4-12.0 (1.3-25.1)
CTA imaging, months	12.0-15.0 (1.0-24.0)
Maximum AAA's diameter <sup>a</sup>	50.8±7.2
Difference AAA's sac <sup>a</sup>	3.0±2.3
Absolute increase	0-0.0%
Stable <sup>b</sup>	27-65.9%
Sac regression $\geq$ 2.5 mm	4-34. %
Notable regression $\geq$ 2.5 mm	8-19.5
and <5 mm	
Important regression $\geq$ 5 mm	6-14.6%
Graft-related endoleak/migration	0-0.0%
Graft-related morbidity/mortality	0-0.0%
Graft-related reinterventions	0-0.0%
Type II endoleak	4–9.8%
Clinical success, 30-day	41-100%
Clinical success, follow-up	41-100%
Clinical success out of IFU	22-100%

#### Early Results of Elective En **Repair of Infrarenal Abdom Aneurysms With the Minos** Stent-Graft System



Journal of Endovascular Therapy

#### Table 2. Outcomes.

Early Results of Elec Repair of Infrarenal Aneurysms With th Stent-Graft System	Abdominal Aortic e Minos <sup>™</sup>	I-B © The Author(s) 2023 © OOO Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/15266028231172379 www.jevt.org S Sage		Mean±SD or Median—IQR (range) or N—%
Dimitrios A. Chatzelas, MD, M	D <sup>I,*</sup> , Apostolos G. Pitoulias, MD, 1Sc <sup>I</sup> , Theodosia Zampaka, MD, MSc <sup>I</sup> , Anastasios Potouridis, MD, I D <sup>I</sup>	MSc <sup>1</sup> ,	Follow-up Clinical, months CTA imaging, months Maximum AAA's diameterª	2.4– 2.0 ( .3–25. )  2.0– 5.0 ( .0–24.0) <u>50.8</u> ±7.2
		ed precise deployme	presented easy navigation even throu, nt, optimal proximal fixation, and po	owerful sealing 9.5
<ul> <li>The results of this preliminary experience in standard EVAR, within as well out of the stend graft's IFU, are promising with excellent feasibility, safety, and effectiveness at first year.</li> <li>The overall clinical performance appeared to be in very high standards.</li> </ul>		0%		
		performance appeare	Clinical success, follow-up Clinical success out of IFU	0% 41–100% 22–100%

#### • Low-profile stent graft (main body 16 - 20 F OD)

<b>Company Name</b>	Product Name	Main Body Delivery System Profile: Device OD (F)
Artivion, Inc.	E-tegra Stent Graft System	18 (<32 mm) 20 (>32 mm)
Cook Medical	Zenith Alpha Abdominal	18 (22–32 mm grafts), 20 (36 mm)
COOK Medical	Zemun Flex with Z-Irak	21, 23, 20
Cordis	Incraft AAA Stent Graft System	$14 (\leq 30 \text{ mm}), 16 (34 \text{ mm})$
Lombard –Medical	Aorfix	18
Lombard – Medical	Altura	14
Lombard - Medical	Minos	14 F (22-28 mm) ; 16 F (30-34 mm)
Endologix	Ovation	14 (≤ 29 mm),15 (34 mm)
Gore & Associates	Gore Excluder C3	16 (< 28.5 mm),18 (≥ 28.5 mm)
Gore & Associates	Gore Excluder Conformable	16 (≤ 28.5 mm),18 (> 28.5 mm)
Medtronic	Endurant II AAA Stent Graft System	18 (≤ 28 mm), 20 (>28 mm)
Medtronic	Endurant II AUI Stent Graft System	18 (≤ 28 mm), 20 (>28 mm)
Medtronic	Endurant IIs AAA Stent Graft System	18 (≤ 28 mm), 20 (>28 mm)
Terumo Aortic	Anaconda	$20 (\leq 30.5\text{-mm}); 22 (\geq 32 \text{ mm})$
Terumo Aortic	Treo	18, 19 (≥ 30 main )



Vascular Surgery – University of Bologna DIMEC, IRCCS University Hospital S. Orsola, Bologna, Italy

### October 2015 - Zenith Alpha<sup>TM</sup> Abdominal



Zenith<sup>®</sup> Alpha<sup>™</sup> Abdominal Endovascular Graft

#### Nitinol

Thin tightly woven dacron (~0.12 mm)

No top cap


#### 16 Fr Flexor 6 mm O.D. (32 mm stent-graft)

Blue rotational handle with integrated releasing mechanism

4 radiopaque markers at the proximal edge of the graft, 1 tick marker at the distal edge of CL limb, 1 marker at the level of the flow-divider, 1 marker at the distal edge of IL limb

 $30\ \mathrm{mm}$  bare suprarenal stentlength

20 mm proximal sealing stent length





#### Cook Zenith Alpha<sup>TM</sup> Abdominal Endograft implantation – Bologna procedure

- Step 1: main body introduction in the juxtarenal aorta,
- Step 2; diagnostic angiography 1° stent deployment,
- Step 3: parallax correction
- Step 4: angiographic control controlateral gate openin
- Step 5: angiographic control, free flow opening
- Step 6: controlateral gate cannulation, marked pig tail, retrograde angiography, iliac leg lenght evaluation
- **Step 7:** minimun overlap, AP projection
- Step 8: projection for hypogastric visualization, iliac limb deployment
- **Step 9:** ipsilateral leg proximal landing zone at the same level of controlateral leg
- Step 10: proximal main-body landing zone PTA (compliant balloon)
- **Step 11:** main body biforcation kissing balloon (semicompliant balloons 12 mm 6 cm)
- Step 12: distal landing zone PTA (compliant balloon if limb diameter  $\geq 18$  mm)
- Step 13: completion aortography with floppy guidewires (AP and LAO-RAO 45°),
- Step 14: femoral retrograde angiography, iliac stenting if residual stenosis is detected



#### The Efficacy of a Protocol of Iliac Artery and Limb Treatment During EVAR in Minimising Early and Late Iliac Occlusion


Andrea Vacirca <sup>\*</sup>, Gianluca Faggioli, Rodolfo Pini, Paolo Spath, Enrico Gallitto, Chiara Mascoli, Mohammad Abualhin, Mauro Gargiulo Vascular Surgery, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy

#### January 2012 - December 2017

- 442 pts, 884 iliac limbs treated
- Protocol of intraoperative iliac limb management
  - for a stenosis morphologically >50% of the lumen of the CIA or EIA on the pre-operative CTA, a non-compliant balloon angioplasty of the stenosed vessel was performed before endograft implantation;
  - the contralateral iliac limb was always deployed precisely at the level of the main body flow divider, even if the endograft IFU allowed its deployment more proximally;
  - the implantation of the aortobi-iliac endograft was always performed over stiff guidewires; after the moulding ballooning of the proximal fixation of the endograft, a kissing non-compliant ballooning was performed at the level of the docking zone between the iliac limbs and the main body of the endograft;
  - after the kissing ballooning of both iliac limbs, selective angiography with a floppy guidewire with different iliac axis angulations was performed. Both iliac limbs were ballooned along their entire length and, in case of flared iliac limb, the distal segment of the limb was dilated with a compliant balloon. For residual extrinsic compression of the iliac limb or kinking of the iliac endoprosthesis, a self expandable bare metal stent, such as Protégé or Everflex Medtronic, Luminexx Bard or Sinus Optimed, was deployed.<sup>13</sup>

- 30 days outcome:
- Perioperative mortality 1.6%ILO 0%
- *Long-term outcome:* . Mean follow up 33± 12 months . **ILO: 0.8%**

**Results** 



# Zenith Alpha Abdominal

Bologna Experience

- ✓ Study period: 2015 2022
- ✓ pts : 231
- ✓ Monocentric study
- ✓ Elective and urgent procedures
- ✓ Mean Follow-up: 33 + 24 months



# Zenith Alpha Abdominal

# Bologna Experience

30-day/in-hospital results

✓ Technical success: 98,7 % (228) of cases (228)

✓ Technical failure: 1,3% (3): 2 Endoleak type Ia; 1 Endoleak type Ib


Reinterventions: 8 (3.5 %) cases:

- 1 Endograft explantation due to Type Ia Endoleak;
- 2 Iliac leg relining due to a Type III Endoleak;
- 1 Iliac leg relining due to a Type Ib Endoleak;
- 2 Inguinal surgical debridement due to wound dehiscence;
- 1 Femoral artery patch angioplasty due to a femoral pseudoaneurysm;
- 1 Hemicolectomy due to acute bowel ischemia (embolization).




✓ Mean Follow-up: 33 + 24 months

- Iliac Limb Occlusion: 3 limbs (1,3%)
- Aortic Shrinkage: 52%










Vascular Surgery – University of Bologna DIMEC, IRCCS University Hospital S. Orsola, Bologna, Italy


### Follow-up results: Reinterventions






Enrico Gallitto, MD, PhD, Gianluca Faggioli, MD, Paolo Spath, MD, Stefano Ancetti, MD, Rodolfo Pini, MD, PhD, Antonino Logiacco, MD, Sergio Palermo, MD, and Mauro Gargiulo, MD, Bologna, Italy

J Vasc Surg 2023;77:106-113








Fig 1. A and B, Angiographic images of contained aortic rupture associated with multiple patent afferent vessels.

# Results

- 45 pts
- Median maximun diameter at the level of PAU:
- The median diameter of aortic bifurcation:
- Bilateral severe femoral or iliac access:
- External iliac artery diameter of less than 7 mm:

49 mm


18 mm (IQR, 3 mm),

13 pts (29%)

7 pts (16%)



### Anatomical Details





Vascular Surgery – University of Bologna DIMEC, IRCCS University Hospital S. Orsola, Bologna, Italy

Enrico Gallitto, MD, PhD, Gianluca Faggioli, MD, Paolo Spath, MD, Stefano Ancetti, MD, Rodolfo Pini, MD, PhD, Antonino Logiacco, MD, Sergio Palermo, MD, and Mauro Gargiulo, MD, Bologna, Italy

J Vasc Surg 2023;77:106-113

@ <b>30-day</b>	n	%
Technical Success	45	100
Morbidity		
Cardiac	1	2
Pulmonary	2	4
Renal	8	18
Reinterventions*	2	4
Mortality**	1	2

\*: femoral access related (Percutaneous 1; Surgical 1)

Early Endpoints

\*\*: Pulmonary complication in urgent patient with preoperative severe COPD




Enrico Gallitto, MD, PhD, Gianluca Faggioli, MD, Paolo Spath, MD, Stefano Ancetti, MD, Rodolfo Pini, MD, PhD, Antonino Logiacco, MD, Sergio Palermo, MD, and Mauro Gargiulo, MD, Bologna, Italy

J Vasc Surg 2023;77:106-113

Follow up Endpoints		n	%
	EL I - III	0	-
✓ Median: 24 (IQR:18) months	Reinterventions	0	-
	PAU enlargement	0	-
	Infection	0	-
	Iliac leg occlusion	0	-
	PAU related mortality	0	-




Enrico Gallitto, MD, PhD, Gianluca Faggioli, MD, Paolo Spath, MD, Stefano Ancetti, MD, Rodolfo Pini, MD, PhD, Antonino Logiacco, MD, Sergio Palermo, MD, and Mauro Gargiulo, MD, Bologna, Italy





Vascular Surgery – University of Bologna DIMEC, IRCCS University Hospital S. Orsola, Bologna, Italy





Vascular Surgery – University of Bologna DIMEC, IRCCS University Hospital S. Orsola, Bologna, Italy



# MARCH 21 & 22 2024

COPENHAGEN/MALMÖ SCANDIC TRIANGELN, MALMÖ

### Low profile devices make it all much easier but are they durable?

- Yes
- This review shows that patients treated with low-profile stent grafts have acceptable mid and long-term outcomes.
- The design evolution toward low-profile platforms seems not to affect the type of complication during the follow-up.
- Long-term surveillance and reintervention, when necessary, remain crucial to guarantee durability.